Replies to post #157 on Amylin Pharmaceuticals Inc. (AMLN)

[north40000]

Icahn Issues Statement Regarding Amylin Pharmaceuticals



NEW YORK, April 25, 2012 /PRNewswire via COMTEX/ -- Carl C. Icahn today
announced that his affiliates had voluntarily dismissed their lawsuit against
Amylin Pharmaceuticals which had sought an extension of the deadline to nominate
directors at the 2012 annual meeting of shareholders. Mr. Icahn released the
following statement:

The decision to discontinue our lawsuit seeking to extend the director
nomination deadline was the result of discussions I had with Daniel Bradbury,
Amylin's chief executive officer, that we agreed would not be publicly
disclosed.

Mr. Icahn reiterated that he continues to strongly believe that the company
should be sold at this time.

[surf1944]

7:13AM Amylin Pharma beats by $0.04, misses on revs (AMLN) 26.20 : Reports Q1 (Mar) loss of $0.23 per share, $0.04 better than the Capital IQ Consensus Estimate of ($0.27); revenues rose 0.7% year/year to $153.7 mln vs the $161.66 mln consensus. The increase in non-GAAP operating loss reflects investments to support the U.S. launch of BYDUREON (exenatide extended-release for injectable suspension)... While still early, we have seen a positive uptake of BYDUREON in the U.S. and Europe, and are pleased with the execution of our U.S. commercial launch... We have also made important progress against our other corporate priorities during the quarter. The recently expanded use of BYETTA with insulin glargine in the U.S. and Europe enables patients to achieve better glycemic control, without weight gain or an increased risk of hypoglycemia. In addition, we recently completed the Biologics License Application submission to the FDA for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in pediatric and adult patients with rare forms of lipodystrophy and are excited to advance this drug for patients who currently have such limited treatment options."